Matches in Nanopublications for { ?s ?p "DDI between Natalizumab and Thiotepa - The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided. [drugbank_resource:DB00108_DB04572]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00108_DB04572 label "DDI between Natalizumab and Thiotepa - The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided. [drugbank_resource:DB00108_DB04572]" assertion.